These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 33140232)

  • 21. Interview with John Patton.
    Patton JS
    Ther Deliv; 2010 Sep; 1(3):375-81. PubMed ID: 22816140
    [No Abstract]   [Full Text] [Related]  

  • 22. Sterile products: advances and challenges in formulation, manufacturing and regulatory aspects--a regulatory review perspective.
    Hussong D
    AAPS PharmSciTech; 2010 Sep; 11(3):1482-4. PubMed ID: 20845091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmaceutical Compounding: The Oldest, Most Symbolic, and Still Vital Part of Pharmacy.
    Kochanowska-Karamyan AJ
    Int J Pharm Compd; 2016; 20(5):367-374. PubMed ID: 28339371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Compounding pharmacy: old methods finding a new niche.
    Matheny C; Martin CM
    Consult Pharm; 2010 Jun; 25(6):357-63. PubMed ID: 20534406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies.
    Yoch D
    Int J Pharm Compd; 2017; 21(2):95-102. PubMed ID: 28346203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Compounding USP <797>: inspection, regulation, and oversight of sterile compounding pharmacies.
    Kastango ES
    JPEN J Parenter Enteral Nutr; 2012 Mar; 36(2 Suppl):38S-39S. PubMed ID: 22275322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Compounding in Ukraine.
    Zdoryk OA; Georgiyants VA; Gryzodub OI; Schnatz R
    Int J Pharm Compd; 2013; 17(2):124-7. PubMed ID: 23696172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How gaps in regulation of compounding pharmacy set the stage for a multistate fungal meningitis outbreak.
    Teshome BF; Reveles KR; Lee GC; Ryan L; Frei CR
    J Am Pharm Assoc (2003); 2014; 54(4):441-5. PubMed ID: 25063265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pharmacist-driven Food and Drug Administration incident surveillance and response program for compounded drugs.
    Janusziewicz AN; Glueck SN; Park SY; Nguyen DN; Rimmel SC; Cascio LA; Doh GY; Martin-Yeboah GF
    Am J Health Syst Pharm; 2021 Jul; 78(15):1438-1443. PubMed ID: 33889929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A brief history of FDA compounding oversight.
    Shulman ST
    Pediatr Ann; 2013 Jan; 42(1):2-3. PubMed ID: 23316818
    [No Abstract]   [Full Text] [Related]  

  • 32. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
    Dorfman HL; Quinn VM; Brophy EA
    Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765
    [No Abstract]   [Full Text] [Related]  

  • 33. A multistate outbreak of Serratia marcescens bloodstream infection associated with contaminated intravenous magnesium sulfate from a compounding pharmacy.
    Sunenshine RH; Tan ET; Terashita DM; Jensen BJ; Kacica MA; Sickbert-Bennett EE; Noble-Wang JA; Palmieri MJ; Bopp DJ; Jernigan DB; Kazakova S; Bresnitz EA; Tan CG; McDonald LC
    Clin Infect Dis; 2007 Sep; 45(5):527-33. PubMed ID: 17682984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fifty Years of Expert Advice - Pharmaceutical Regulation and the Legacy of the Drug Efficacy Study.
    Schwartz JL
    N Engl J Med; 2016 Nov; 375(21):2015-2017. PubMed ID: 27959733
    [No Abstract]   [Full Text] [Related]  

  • 35. Using market-exclusivity incentives to promote pharmaceutical innovation.
    Kesselheim AS
    N Engl J Med; 2010 Nov; 363(19):1855-62. PubMed ID: 21047231
    [No Abstract]   [Full Text] [Related]  

  • 36. The regulatory framework for preventing cross-contamination of pharmaceutical products: History and considerations for the future.
    Sargent EV; Flueckiger A; Barle EL; Luo W; Molnar LR; Sandhu R; Weideman PA
    Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S3-S10. PubMed ID: 27230736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A systematic review and meta-analysis of microbial contamination of parenteral medication prepared in a clinical versus pharmacy environment.
    Larmené-Beld KHM; Frijlink HW; Taxis K
    Eur J Clin Pharmacol; 2019 May; 75(5):609-617. PubMed ID: 30683970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. America's first drug regulation regime: the rise and fall of the Import Drug Act of 1848.
    Heath WJ
    Food Drug Law J; 2004; 59(1):169-99. PubMed ID: 15212037
    [No Abstract]   [Full Text] [Related]  

  • 39. Extemporaneous compounding: a return to regulatory limbo?
    Winckler SC
    J Pain Palliat Care Pharmacother; 2002; 16(4):71-8. PubMed ID: 14635828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Drug counterfeiting and counter measures. Study by the Hungarian National Alliance Against Drug Counterfeiting].
    Psychiatr Hung; 2009; 24(3):205-14. PubMed ID: 20017282
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.